Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
Rhea-AI Summary
Rani Therapeutics (NASDAQ: RANI), a clinical-stage biotherapeutics company, has announced a $3.0 million registered direct offering of its Class A common stock and pre-funded warrants. The company will sell 4,354,000 shares at $0.40 per share and pre-funded warrants for 3,146,000 shares at $0.3999 to a single institutional investor.
The offering, expected to close around July 16, 2025, is being conducted through Maxim Group LLC as the sole placement agent. The pre-funded warrants will have an exercise price of $0.0001 per share. The offering is made pursuant to an effective shelf registration statement, with proceeds subject to placement agent fees and offering expenses.
Positive
- Secured immediate funding of $3.0 million through registered direct offering
- Single institutional investor commitment shows continued interest in the company
Negative
- Significant dilution to existing shareholders with issuance of 7.5 million new shares/warrants
- Low offering price of $0.40 per share suggests weak market position
- Small offering size of $3.0M indicates limited funding secured
News Market Reaction – RANI
In the trading session that priced this news, RANI declined 38.92%, reflecting a significant negative market reaction. Argus tracked a trough of -19.9% from its starting point during tracking. Our momentum scanner triggered 42 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 3.4x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 4,354,000 shares of Rani Therapeutics’ Class A common stock at a purchase price of
Maxim Group LLC is acting as the sole placement agent for the offering.
The offering is expected to close on or about July 16, 2025, subject to satisfaction of customary closing conditions. The gross proceeds to Rani Therapeutics from this offering are expected to be approximately
The securities in the registered direct offering are being offered and sold by Rani pursuant to a "shelf" registration statement on Form S-3 (File No. 333-266444) which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on August 10, 2022. The offering of the securities is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
